Bristol-myers Squibb Compnay

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Bristol-myers Squibb Holdings Ireland

Omar D Lopez

Makonen Belema

Nicholas A Meanwell

Jeffrey Lee Romine

Denis R St Laurent

Lawrence B Snyder

Van N Nguyen

Jason T Goodrich

Fukang Yang

Lawrence G Hamann

Andrew Charles Good

Rico Lavoie

Edward H Ruediger

David R Langley

Alain Martel

Carol Bachand

Daniel H Deon

Clint A James

Gan Wang

Piyasena Hewawasam

John A Bender

John F Kadow

Ningning Xu

Qi Chen

Alan Xiangdong Wang

Yong Tu

Michael H Serrano-Wu

Yuping Qiu

Samayamunthula Venkata Satya Arun Kumar Gupta

Ramesh Kakarla

John E Starrett, Jr

Zhong Yang

Xuejie Yang

Donn Gregory Wishka

Jayne Kapur

Joel Morris

Mark George Saulnier

Min Ding

Kevin W Gillman

David Bertil Frennesson

Min Gao

Hasibur Rahaman

Michael J Smith

Guo Li

William D Schmitz

Julie A Lemm

David Paul Provencal

Ying-Kai Wang

Robert A Fridell

Lianhao Zhang

Pothukanuri Srinivasu

Donald R O'Boyle, Ii

Jin-Hua Sun

Sergiy M Denysenko

Baburao Vishnuvajjala

Robert Bahde

Indasi J Gopi Kumar

Suresh Kumar Ponugupati

Indasi Gopi Kumar

Ponugupati Suresh Kumar

Roshan Yadavrao Nimje

Chunfu Wang

John A Easter

Bao-Ning Su

Piyasena Hewawasa

Suresh Kumar Punugupati

Donald R O'BOYLE Ii

Belema Makonen

Methods for stereoselective synthesis and manufacturing of 2'-deoxynucleosides, such as 2&#x2032;-ribonucleosides, are disclosed. In some embodiments, the 2&#x2032;-deoxynucleoside is a &#x3b2;-anomer of a 2&#x2032;-deoxynucleoside having a 3&#x2032; &#x3b1; hydroxyl, 4&#x2032; &#x3b2; hydroxymethyl configuration. Nonlimiting examples of compounds prepared by the disclosed methods include 4&#x2032;-thio-2&#x2032;-deoxycytidine (T-dCyd) and 5-aza-4&#x2032;-thio-2&#x2032;-deoxycytidine (5-aza-T-dCyd; aza-T-dCyd; aza-T-dC).

Stereoselective synthesis and process for the manufacturing of 2'-deoxynucleosides

Halogenated analogs of 5-aza-2'-deoxycytidine, such as halogenated analogs of 5-aza-4&#x2032;-thio-2&#x2032;-deoxycytidine (5-aza-T-dCyd) are described. Pharmaceutical compositions including a halogenated analog and methods of using the halogenated analogs to inhibit neoplasia are described. In some examples, the halogenated analogs have a structure according to formula Ia, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: 

2'-halogenated-4&#x2032;-thio-2&#x2032;-deoxy-5-azacytidine analogs and use thereof

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

Growing community of inventors

Wallingford, CT, United States of America

Omar D Lopez